CN106191062A - 一种tcr‑/pd‑1‑双阴性t细胞及其构建方法 - Google Patents
一种tcr‑/pd‑1‑双阴性t细胞及其构建方法 Download PDFInfo
- Publication number
- CN106191062A CN106191062A CN201610570655.1A CN201610570655A CN106191062A CN 106191062 A CN106191062 A CN 106191062A CN 201610570655 A CN201610570655 A CN 201610570655A CN 106191062 A CN106191062 A CN 106191062A
- Authority
- CN
- China
- Prior art keywords
- tcr
- sgrna
- crispr
- seq
- cas9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010276 construction Methods 0.000 title claims abstract description 16
- 210000003515 double negative t cell Anatomy 0.000 title claims description 32
- 101710089372 Programmed cell death protein 1 Proteins 0.000 title abstract description 34
- 102100040678 Programmed cell death protein 1 Human genes 0.000 title abstract description 33
- 108091033409 CRISPR Proteins 0.000 claims abstract description 139
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 117
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 72
- 210000004027 cell Anatomy 0.000 claims abstract description 46
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims abstract description 5
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 128
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 66
- 108091034117 Oligonucleotide Proteins 0.000 claims description 58
- 230000000295 complement effect Effects 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 102000053602 DNA Human genes 0.000 claims description 25
- 230000002441 reversible effect Effects 0.000 claims description 18
- 238000001890 transfection Methods 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 11
- 208000030507 AIDS Diseases 0.000 claims description 10
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 10
- 241000700721 Hepatitis B virus Species 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 34
- 238000009169 immunotherapy Methods 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 10
- 230000001413 cellular effect Effects 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 7
- 239000011324 bead Substances 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000010362 genome editing Methods 0.000 abstract description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 33
- 230000000694 effects Effects 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 21
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 230000009471 action Effects 0.000 description 12
- 230000007850 degeneration Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 238000000137 annealing Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 229960003301 nivolumab Drugs 0.000 description 6
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000003151 transfection method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 239000012570 Opti-MEM I medium Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 238000010459 TALEN Methods 0.000 description 3
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- SJQBHPJLLIJASD-UHFFFAOYSA-N 3,3',4',5-tetrachlorosalicylanilide Chemical compound OC1=C(Cl)C=C(Cl)C=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 SJQBHPJLLIJASD-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 102100039087 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Human genes 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000037111 immune power Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011337 individualized treatment Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940055760 yervoy Drugs 0.000 description 2
- SNKNNAPOEZWYCH-UHFFFAOYSA-N (2-hydroxy-3-piperidin-1-ylpropyl) n-phenylcarbamate;hydrochloride Chemical compound Cl.C1CCCCN1CC(O)COC(=O)NC1=CC=CC=C1 SNKNNAPOEZWYCH-UHFFFAOYSA-N 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 101710172824 CRISPR-associated endonuclease Cas9 Proteins 0.000 description 1
- 101150043916 Cd52 gene Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- -1 TCR) therapy (TCRT) Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000012177 large-scale sequencing Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 101150054448 pdl-1 gene Proteins 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
Description
成分 | 用量 |
DNA | 200ng |
10×NEB Buffer2 | 2μl |
ddH2O | 加到19.5μL |
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610570655.1A CN106191062B (zh) | 2016-07-18 | 2016-07-18 | 一种tcr-/pd-1-双阴性t细胞及其构建方法 |
PCT/CN2016/094617 WO2018014384A1 (zh) | 2016-07-18 | 2016-08-11 | 一种tcr-/pd-1-双阴性t细胞及其构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610570655.1A CN106191062B (zh) | 2016-07-18 | 2016-07-18 | 一种tcr-/pd-1-双阴性t细胞及其构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106191062A true CN106191062A (zh) | 2016-12-07 |
CN106191062B CN106191062B (zh) | 2019-06-14 |
Family
ID=57494231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610570655.1A Active CN106191062B (zh) | 2016-07-18 | 2016-07-18 | 一种tcr-/pd-1-双阴性t细胞及其构建方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN106191062B (zh) |
WO (1) | WO2018014384A1 (zh) |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107058315A (zh) * | 2016-12-08 | 2017-08-18 | 上海优卡迪生物医药科技有限公司 | 敲减人PD‑1的siRNA、重组表达CAR‑T载体及其构建方法和应用 |
CN107619821A (zh) * | 2017-10-13 | 2018-01-23 | 北京瑞健科技有限公司 | 一种类似嵌合抗原受体修饰的cik及其制备方法与应用 |
CN107699591A (zh) * | 2017-05-09 | 2018-02-16 | 山东兴瑞生物科技有限公司 | 一种敲除pd‑1的t细胞制备方法及其应用 |
CN107828730A (zh) * | 2017-11-07 | 2018-03-23 | 南京北恒生物科技有限公司 | 具有抗体药物抗性的通用型cart/tcrt细胞及其构建方法 |
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
WO2018137293A1 (zh) * | 2017-01-25 | 2018-08-02 | 北京马力喏生物科技有限公司 | 治疗间质素阳性肿瘤的治疗组合物 |
CN108503710A (zh) * | 2018-03-30 | 2018-09-07 | 徐州逸仕生物技术有限公司 | 程序性死亡受体1抗体磁珠的制备方法及其应用 |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
CN109055380A (zh) * | 2018-09-19 | 2018-12-21 | 深圳市菲鹏生物治疗股份有限公司 | 一种通用型car-t细胞的制备方法 |
WO2018233596A1 (zh) | 2017-06-20 | 2018-12-27 | 江苏恒瑞医药股份有限公司 | 体外敲除T细胞中靶基因的方法以及该方法中使用的crRNA |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
CN109136278A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种mrfft1细胞 |
CN109136190A (zh) * | 2018-04-11 | 2019-01-04 | 北京中诚华科生物科技有限公司 | 一种抵抗肿瘤免疫抑制环境的btla-/-t淋巴细胞的制备方法与应用 |
WO2019011118A1 (zh) * | 2017-07-14 | 2019-01-17 | 苏州克睿基因生物科技有限公司 | 一种基因编辑系统及基因编辑的方法 |
CN109295106A (zh) * | 2018-09-30 | 2019-02-01 | 北京鼎成肽源生物技术有限公司 | 一种hafft1细胞 |
CN109370992A (zh) * | 2018-09-28 | 2019-02-22 | 深圳市菲鹏生物治疗股份有限公司 | 一种通用型car-t细胞的纯化方法 |
CN109652378A (zh) * | 2018-12-29 | 2019-04-19 | 广州百暨基因科技有限公司 | 一种功能增强的通用型car-t细胞及其制备方法和用途 |
CN109722437A (zh) * | 2018-12-29 | 2019-05-07 | 广州百暨基因科技有限公司 | 一种通用型car-t细胞及其制备方法和用途 |
CN109837244A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向cd19的嵌合抗原受体t细胞及其制备方法和应用 |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
WO2019237392A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | CRISPR/Cas9靶向敲除人SLEB2基因及其特异性gRNA |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
WO2020088631A1 (en) | 2018-11-01 | 2020-05-07 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
CN111676195A (zh) * | 2019-03-11 | 2020-09-18 | 北京卡替医疗技术有限公司 | 一种治疗t细胞肿瘤的ucar免疫细胞 |
JP2020534869A (ja) * | 2017-09-18 | 2020-12-03 | 博雅▲輯▼因(北京)生物科技有限公司Edigene Inc. | 遺伝子編集t細胞及びその使用 |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108753817A (zh) * | 2018-04-13 | 2018-11-06 | 北京华伟康信生物科技有限公司 | 增强细胞的抗癌能力的方法及采用该方法获得的增强型细胞 |
JP2021523745A (ja) | 2018-05-16 | 2021-09-09 | シンテゴ コーポレイション | ガイドrna設計および使用のための方法およびシステム |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103820454A (zh) * | 2014-03-04 | 2014-05-28 | 黄行许 | CRISPR-Cas9特异性敲除人PD1基因的方法以及用于特异性靶向PD1基因的sgRNA |
WO2015164740A1 (en) * | 2014-04-24 | 2015-10-29 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
CN105228640A (zh) * | 2013-02-26 | 2016-01-06 | 王荣福 | Phf20和jmjd3组合物及其在肿瘤免疫治疗中的使用方法 |
WO2016069282A1 (en) * | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2969417A1 (en) * | 2014-12-05 | 2016-06-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
CN105671083B (zh) * | 2016-02-03 | 2017-09-29 | 安徽柯顿生物科技有限公司 | PD‑1基因重组病毒质粒及构建、重组逆转录病毒Lenti‑PD‑1‑Puro及包装与应用 |
-
2016
- 2016-07-18 CN CN201610570655.1A patent/CN106191062B/zh active Active
- 2016-08-11 WO PCT/CN2016/094617 patent/WO2018014384A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105228640A (zh) * | 2013-02-26 | 2016-01-06 | 王荣福 | Phf20和jmjd3组合物及其在肿瘤免疫治疗中的使用方法 |
CN103820454A (zh) * | 2014-03-04 | 2014-05-28 | 黄行许 | CRISPR-Cas9特异性敲除人PD1基因的方法以及用于特异性靶向PD1基因的sgRNA |
WO2015164740A1 (en) * | 2014-04-24 | 2015-10-29 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
WO2016069282A1 (en) * | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
WO2016069283A1 (en) * | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in cart cells and uses thereof |
Non-Patent Citations (1)
Title |
---|
邵红伟等: "CRISPR-Cas9系统定向编辑TCR基因的sgRNA筛选", 《集美大学学报(自然科学版)》 * |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11242530B2 (en) | 2016-12-08 | 2022-02-08 | Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd | siRNA knocking down human PD-1 and recombinant expression CAR-T vector and their construction methods and applications |
JP2019534711A (ja) * | 2016-12-08 | 2019-12-05 | 上海優▲か▼迪生物医薬科技有限公司Shanghai Unicar−Therapy Bio−Medicine Technology Co.,Ltd | ヒトPD−1をノックダウンしたsiRNA、組換え発現CAR−Tベクターおよびその構築方法と使用 |
WO2018103501A1 (zh) * | 2016-12-08 | 2018-06-14 | 上海优卡迪生物医药科技有限公司 | 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用 |
CN107058315A (zh) * | 2016-12-08 | 2017-08-18 | 上海优卡迪生物医药科技有限公司 | 敲减人PD‑1的siRNA、重组表达CAR‑T载体及其构建方法和应用 |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
WO2018137293A1 (zh) * | 2017-01-25 | 2018-08-02 | 北京马力喏生物科技有限公司 | 治疗间质素阳性肿瘤的治疗组合物 |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
CN107699591B (zh) * | 2017-05-09 | 2020-06-09 | 山东兴瑞生物科技有限公司 | 一种敲除pd-1的t细胞制备方法及其应用 |
CN107699591A (zh) * | 2017-05-09 | 2018-02-16 | 山东兴瑞生物科技有限公司 | 一种敲除pd‑1的t细胞制备方法及其应用 |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
WO2018233596A1 (zh) | 2017-06-20 | 2018-12-27 | 江苏恒瑞医药股份有限公司 | 体外敲除T细胞中靶基因的方法以及该方法中使用的crRNA |
WO2019011118A1 (zh) * | 2017-07-14 | 2019-01-17 | 苏州克睿基因生物科技有限公司 | 一种基因编辑系统及基因编辑的方法 |
CN111278980A (zh) * | 2017-07-14 | 2020-06-12 | 苏州克睿基因生物科技有限公司 | 一种基因编辑系统及基因编辑的方法 |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
JP2020534869A (ja) * | 2017-09-18 | 2020-12-03 | 博雅▲輯▼因(北京)生物科技有限公司Edigene Inc. | 遺伝子編集t細胞及びその使用 |
JP7190096B2 (ja) | 2017-09-18 | 2022-12-15 | 博雅▲緝▼因(北京)生物科技有限公司 | 遺伝子編集t細胞及びその使用 |
CN107619821A (zh) * | 2017-10-13 | 2018-01-23 | 北京瑞健科技有限公司 | 一种类似嵌合抗原受体修饰的cik及其制备方法与应用 |
CN107619821B (zh) * | 2017-10-13 | 2020-02-07 | 北京舜雷科技有限公司 | 一种类似嵌合抗原受体修饰的cik及其制备方法与应用 |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
CN107828730A (zh) * | 2017-11-07 | 2018-03-23 | 南京北恒生物科技有限公司 | 具有抗体药物抗性的通用型cart/tcrt细胞及其构建方法 |
CN109837244A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向cd19的嵌合抗原受体t细胞及其制备方法和应用 |
CN108503710A (zh) * | 2018-03-30 | 2018-09-07 | 徐州逸仕生物技术有限公司 | 程序性死亡受体1抗体磁珠的制备方法及其应用 |
CN109136190A (zh) * | 2018-04-11 | 2019-01-04 | 北京中诚华科生物科技有限公司 | 一种抵抗肿瘤免疫抑制环境的btla-/-t淋巴细胞的制备方法与应用 |
WO2019237392A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | CRISPR/Cas9靶向敲除人SLEB2基因及其特异性gRNA |
CN109055380A (zh) * | 2018-09-19 | 2018-12-21 | 深圳市菲鹏生物治疗股份有限公司 | 一种通用型car-t细胞的制备方法 |
CN109370992A (zh) * | 2018-09-28 | 2019-02-22 | 深圳市菲鹏生物治疗股份有限公司 | 一种通用型car-t细胞的纯化方法 |
CN109295106A (zh) * | 2018-09-30 | 2019-02-01 | 北京鼎成肽源生物技术有限公司 | 一种hafft1细胞 |
CN109295106B (zh) * | 2018-09-30 | 2020-07-24 | 北京鼎成肽源生物技术有限公司 | 一种hafft1细胞 |
CN109136278B (zh) * | 2018-09-30 | 2020-09-29 | 北京鼎成肽源生物技术有限公司 | 一种mrfft1细胞 |
CN109136278A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种mrfft1细胞 |
WO2020088631A1 (en) | 2018-11-01 | 2020-05-07 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
CN113383071A (zh) * | 2018-11-01 | 2021-09-10 | 亘喜生物科技(上海)有限公司 | 用于t细胞工程化的组合物和方法 |
CN109722437A (zh) * | 2018-12-29 | 2019-05-07 | 广州百暨基因科技有限公司 | 一种通用型car-t细胞及其制备方法和用途 |
CN109722437B (zh) * | 2018-12-29 | 2020-01-07 | 广州百暨基因科技有限公司 | 一种通用型car-t细胞及其制备方法和用途 |
CN109652378A (zh) * | 2018-12-29 | 2019-04-19 | 广州百暨基因科技有限公司 | 一种功能增强的通用型car-t细胞及其制备方法和用途 |
CN111676195A (zh) * | 2019-03-11 | 2020-09-18 | 北京卡替医疗技术有限公司 | 一种治疗t细胞肿瘤的ucar免疫细胞 |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Also Published As
Publication number | Publication date |
---|---|
CN106191062B (zh) | 2019-06-14 |
WO2018014384A1 (zh) | 2018-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106191062B (zh) | 一种tcr-/pd-1-双阴性t细胞及其构建方法 | |
Cordova et al. | Human SLC46A2 is the dominant cGAMP importer in extracellular cGAMP-sensing macrophages and monocytes | |
CN105671083B (zh) | PD‑1基因重组病毒质粒及构建、重组逆转录病毒Lenti‑PD‑1‑Puro及包装与应用 | |
Maus et al. | Adoptive immunotherapy for cancer or viruses | |
CN101918544B (zh) | 提高免疫反应性的方法 | |
CN105296431B (zh) | 肿瘤结合特异性γδTCR基因修饰的αβT细胞及其抑癌用途 | |
CN107630006A (zh) | 一种制备tcr与hla双基因敲除的t细胞的方法 | |
EA016168B1 (ru) | Способ получения т-клеточной популяции и ее применение | |
CN105777911A (zh) | 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 | |
CN107075480A (zh) | γδT细胞及其用途 | |
CN108409840A (zh) | 抗cd123单链抗体及其组合的嵌合抗原受体和应用 | |
CN105820255B (zh) | 抗cd33嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 | |
CN105924533A (zh) | Ror1特异性嵌合抗原受体及其应用 | |
Circelli et al. | Immunological effects of a novel RNA-based adjuvant in liver cancer patients | |
CN109055430A (zh) | 一种共表达il18和ccl19蛋白及靶向muc1基因car-t细胞的制备方法 | |
CN105950663B (zh) | 一种靶向cd30的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用 | |
CN104262459B (zh) | 一种急性单核细胞白血病相关抗原mlaa‑34 表位多肽及其疫苗和制药应用 | |
CN109021114B (zh) | 联合两种单链抗体的双特异性嵌合抗原受体及表达载体 | |
NZ555571A (en) | Alpha thymosin peptides as cancer vaccine adjuvants | |
CN106589133A (zh) | 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用 | |
CN110016465A (zh) | 一种包含b细胞及肿瘤双识别性t细胞的免疫细胞药物 | |
CN105950662B (zh) | 一种靶向cd22的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用 | |
CN107602703A (zh) | 靶向人EpCAM的基因工程化淋巴细胞及其制备方法和用途 | |
Grzybowski et al. | Novel dual arginase 1/2 inhibitor OATD-02 (OAT-1746) improves the efficacy of immune checkpoint inhibitors | |
CN108203717A (zh) | 能靶向Her2并干扰PD-1降低肿瘤免疫逃逸的CAR-T载体及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Moon Road, Science City high tech Industrial Development Zone of Guangzhou City, Guangdong province 510663 No. 3 Guangzhou international business incubator F F715. Applicant after: Guangdong Southern China vaccine Limited by Share Ltd Address before: The city on 510663 Guangzhou Road, Guangdong province science No. 3 international business incubator F building 7 floor Applicant before: Southern China United Vaccine Institute Co., Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190904 Address after: 510535 No. 1 Ruifa Road, Huangpu District, Guangzhou City, Guangdong Province, Room 203 on the second floor of Building 1 (1) (self-declared) Patentee after: Guangzhou Anjie Biomedical Technology Co., Ltd. Address before: 510663 Room F715, Guangzhou International Business Incubator Area F, No. 3 Lanyue Road, Science City, Guangzhou High-tech Industrial Development Zone, Guangdong Province Patentee before: Guangdong Southern China vaccine Limited by Share Ltd |
|
TR01 | Transfer of patent right |